Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G‐EPOSS study
S. Gerdes,R. Ostendorf,A. Süß,T. Schadeck,F. Taut,J. Makuc,L. Scharfenberger,S. Jacobsen,N. Trenkler,J. Behrens,G. Joks,S. Tabori,D. Mortazawi
DOI: https://doi.org/10.1111/jdv.19927
2024-04-13
Journal of the European Academy of Dermatology and Venereology
Abstract:Background G‐EPOSS is a prospective, non‐interventional, German multicentre study of patients with moderate‐to‐severe plaque psoriasis receiving guselkumab, a therapeutic monoclonal antibody targeting interleukin‐23, in a real‐world setting. Objectives The objective of the study was to evaluate the effectiveness and safety of guselkumab, including its impact on skin, health‐related quality of life (HRQoL), sexuality, and perceived stigmatization. Methods Patients (≥18 years old) received guselkumab per routine clinical practice. The primary endpoint was the proportion of patients achieving absolute Psoriasis Area and Severity Index (PASI) ≤ 3 at Week (W)28. Secondary endpoint assessments over 28 weeks included the Nail Psoriasis Severity Index (NAPSI), anogenital Physician's Global Assessment (aPGA), and Dermatology Life Quality Index (DLQI). Sexuality and perceived stigmatization were assessed by patients using the Relationship and Sexuality Scale (RSS) and Perceived Stigmatization Questionnaire (PSQ), respectively. Results Overall, 293 patients were included in the evaluable set population. Mean age and disease duration were 45.6 and 17.6 years, respectively. At baseline, mean PASI, aPGA and DLQI scores were 15.3, 2.7 and 11.3, respectively. In total, 25.9% of patients had received a prior biologic. Overall, 83.0% of patients achieved PASI ≤ 3, and 56.2%/35.1% achieved PASI ≤ 1/PASI = 0, respectively, at W28. Among those with NAPSI ≥ 1 and aPGA ≥ 1 at baseline, NAPSI = 0 and aPGA = 0 were achieved by 39.2% and 61.1% of patients, respectively, and 61.4% of patients achieved DLQI 0–1 at W28. Improvements were observed over 28 weeks across individual items of the DLQI, RSS and PSQ, indicating improved HRQoL and sex life, and decreased perceived stigmatization. Based on DLQI Question (Q)9, 53.6% of patients experienced sexual difficulties at baseline, which decreased to 12.1% at W28. DLQI Q9 responses were consistent with RSS item responses, highlighting DLQI Q9 as a sentinel for sexual impairment. Conclusions Guselkumab improved overall skin symptoms and HRQoL in patients with psoriasis and decreased sexual impairment and perceived stigmatization. No new safety signals were observed. Study code CNTO1959PSO4008.
dermatology